Got 90 seconds? Then listen to TruScreen CEO Martin Dillon tell us about his AusBiotech Invest presentation and the company’s near term growth drivers.

TruScreen Limited (NZX:TRU) is a medtech company focused on the development and sale of devices that provide real-time screening of cervical cancer.

The company uses a sophisticated proprietary algorithm to distinguish between normal and abnormal tissue to identify precancerous change, or cervical intraepithelial neoplasia (a precancerous condition).

TruScreen’s commercialisation strategy is built around entering developing countries where there is limited or no large scale cervical cancer screening programs or infrastructure in place. TruScreen has a competitive advantage in these markets, as the company’s cervical cancer screening devices require little laboratory infrastructure.

We caught up with the company’s CEO Martin Dillon at the 2019 AusBiotech event and gave him 90 Seconds to tell us more about the company.

Have a good idea for our next 90 Seconds With segment? Email us at tv@stockhead.com.au.